Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 13/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 2/20 | 0.34 |
| ▸ | FLT4 | P35916 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822583 | 0.93 | MAPK9 (0.43) | MAPK9MAPK10KDRP2RX4KDM4E | |
| SCHEMBL822749 | 0.90 | MAPK9 (0.40) | MAPK9MAPK10KDRP2RX4KDM4E | |
| SCHEMBL822726 | 0.90 | MAPK9 (0.56) | MAPK9MAPK10KDRP2RX4MAOA | |
| SCHEMBL822604 | 0.87 | P2RX4 (0.38) | MAPK9MAPK10KDRP2RX4KDM4E | |
| SCHEMBL822584 | 0.86 | MAPK9 (0.39) | MAPK9MAPK10KDRP2RX4MAOA | |
| SCHEMBL9920528 | 0.85 | MAPK9 (0.36) | MAPK9MAPK10KDRP2RX4MAOA | |
| SCHEMBL822602 | 0.84 | ALDH1A1 (0.45) | MAPK9MAPK10KDM4EATML3MBTL1 | |
| SCHEMBL9920554 | 0.81 | MAPK9 (0.47) | MAPK9MAPK10KDRP2RX4MAOA | |
| SCHEMBL12219217 | 0.80 | KDM4E (0.50) | KDRKDM4EATML3MBTL1MAOA | |
| SCHEMBL280277 | 0.80 | MAPK9 (0.45) | MAPK9MAPK10KDRP2RX4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067919-B2 | Use of dibenzofurans and dibenzothiophenes substituted by nitrogen-bonded five-membered heterocyclic rings in organic electronics | BASF SE (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | BASF SE (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120007063-A1 | USE OF DIBENZOFURANS AND DIBENZOTHIOPHENES SUBSTITUTED BY NITROGEN-BONDED FIVE-MEMBERED HETEROCYCLIC RINGS IN ORGANIC ELECTRONICS | DDT, DBF4, POU5F1 | MAPK9 3614/4885MAPK10 3165/4885KDR 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.